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Introduction: Understanding the multiple biological functions played by human mesenchymal stem cells (hMSCs)
as well as their development as therapeutics in regenerative medicine or in cancer treatment are major fields of
research. Indeed, it has been established that hMSCs play a central role in the pathogenesis and progression of
tumours, but their impact on tumour growth remains controversial.
Methods: In this study, we investigated the influence of hMSCs on the growth of pre-established tumours. We
engrafted nude mice with luciferase-positive mouse adenocarcinoma cells (TSA-Luc+) to obtain subcutaneous or
lung tumours. When tumour presence was confirmed by non-invasive bioluminescence imaging, hMSCs were
injected into the periphery of the SC tumours or delivered by systemic intravenous injection in mice bearing either
SC tumours or lung metastasis.
Results: Regardless of the tumour model and mode of hMSC injection, hMSC administration was always associated
with decreased tumour growth due to an inhibition of tumour cell proliferation, likely resulting from deep
modifications of the tumour angiogenesis. Indeed, we established that although hMSCs can induce the formation
of new blood vessels in a non-tumoural cellulose sponge model in mice, they do not modify the overall amount of
haemoglobin delivered into the SC tumours or lung metastasis. We observed that these tumour vessels were
reduced in number but were longer.
Conclusions: Our results suggest that hMSCs injection decreased solid tumour growth in mice and modified tumour
vasculature, which confirms hMSCs could be interesting to use for the treatment of pre-established tumours.Introduction
Mesenchymal stem cells (MSCs), also referred to as stromal
progenitor cells, reside in the adult bone marrow, are
capable of self-renewal and can be quickly expanded
in vitro. Under appropriate experimental conditions,
MSCs can differentiate into a number of mesodermal
cell lineages, including bone, cartilage, stroma, adipose
tissue, connective tissue, muscle and tendon [1-3]. MSCs
also have immunosuppressive properties that can be
exploited for the treatment of autoimmune or graft-versus-
host diseases [4].
Moreover, MSCs possess an innate tropism for sites of
injury irrespective of tissue or organ type. MSCs have* Correspondence: Claire.rome@ujf-grenoble.fr
†Equal contributors
1Inserm U823, Institut Albert Bonniot, Université Joseph Fourier, Rond-Point
de la Chantourne, Grenoble 38706, France
Full list of author information is available at the end of the article
© 2013 Kéramidas et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumbeen shown to specifically home to tumour and metasta-
sis sites in multiple types of cancers [5]. The tropism of
MSCs for tumours is thought to be due to a similarity in
the factors secreted by wounds and tumours, which has
led to the hypothesis that tumours resemble chronic
wounds or ‘wounds that never heal’ [6]. Thus, MSCs
have been studied as potential anti-tumour cells and as
vehicles for gene therapy [7].
However, the role of native MSCs inside the tumour
microenvironment is unclear, and the relationship between
MSCs and tumour cells is complicated; MSCs have been
linked to contradictory effects on tumour growth [8-11].
This dual influence of MSCs is also present in the
angiogenic process. MSCs are capable of inducing
neoangiogenesis in vitro [12,13] and in vivo [14-16]. In
addition, they can differentiate into endothelial cells
[17,18] and/or pericytes [19]. In some tumour models,
grafted MSCs were shown to settle into the tumourtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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an increase in tumour growth [21]. In contrast, in other
tumour models, MSCs have been reported to abrogate
tumour growth by pushing endothelial cells to enter
programmed cell death [22].
To clarify this issue, we studied the impact of hu-
man mesenchymal stem cells (hMSC) injection on pre-
established tumours. We demonstrated that hMSC
administration decreases tumour growth when injected
systemically or directly in contact with the tumours,
suggesting a systemic effect. This effect is clearly cor-
related with an inhibition of tumour cell proliferation.
Furthermore, we established that although hMSCs
induced physiological angiogenesis in vivo, these cells
do not alter the overall pathological angiogenesis of the
tumours. However, administration of hMSCs induced
significant remodelling of the tumour vasculature. These
observations suggest that tumour vasculature normalisation
is induced by the presence of hMSCs.
Materials and methods
Cell culture
TSA-pGL3 is a cell line derived from the murine mammary
adenocarcinoma TS/A-pc cell line comes from spon-
taneous mammary tumour cells [23] that has been sta-
bly transfected with the pGL3-luciferase reporter gene
(Promega, Charbonnières, France). Cells were cultured
at 37°C in a humidified 5% CO2 incubator in RPMI
1640 media supplemented with 1% glutamine, 10%
foetal bovine serum, 50 units/ml penicillin, 50 μg/mL
streptomycin, 25 μM β-mercaptoethanol and 700 μg/ml
Geneticin™ (G418 sulphate; Gibco, Paisley, UK).
hMSCs were isolated from bone marrow aspirates
from three healthy donors, each of whom gave informed
consent. All the isolation and culture procedures
were conducted in the authorized cell therapy unit
(Biotherapy Team of the General Clinical Research Center,
French Health Minister agreement TCG/04/0/008/AA) at
the Grenoble University Hospital. The cells were cultured
at 37°C in a humidified atmosphere containing 5% CO2
according to a previously described method [24]. Briefly,
hMSCs were selected by plastic adhesion and cultured
in Minimum Essential Eagle Medium alpha (MEMα)
supplemented with 100 μg/mL penicillin, 100 μg/mL
streptomycin, and 10% foetal calf serum (FCS) (all reagents
from Invitrogen, Cergy Pontoise, France). All the hMSCs
used were phenotyped by FACS analysis and their function-
ality was tested (colony-forming units and in vitro differen-
tiation in adipocyte and osteoblast [24]) (data not shown).
Cell implantation in mice
All animal experiments were conducted in adherence
to the Principles of Laboratory Animal Care (National
Institutes of Health publication no. 86–23, revised 1985)and approved by the regional ethics committee (Reference
number of animal experiments: 96_IAB-U823 MK-09
and 97_IAB-U823 MK-08; Comité d’éthique en expéri-
mentation animale de Grenoble: Com-Eth, amended
by the Comité National de Réflexion Ethique sur
l’Expérimentation Animale (No.12)). Female athymic
NMRI nude mice, purchased from Janvier (Le Genest Saint
Isle, France) at 6 to 8 weeks of age, were maintained under
specific pathogen-free conditions. We choose to inject the
TSA-pGL3 cell line (1) subcutaneously because it is an easy
model to follow and visualize and (2) intravenously to
mimic a more physiological lung metastasis model [25]
(Figure 1). The subcutaneous (SC) injection of 106 TSA-
pGL3 cells suspended in 200 μL of PBS into the right flank
of mice resulted in the formation of 6 to 8 mm-diameter
tumours after one week. Intravenous (IV) injection of 105
TSA-pGL3 cells suspended in 200 μL of PBS into the tail
vein resulted in tumour lung nodule formation at day 4.
At these times, animals were randomised into groups
(n = 5 per group), and 5 × 105 hMSCs were injected
subcutaneously at the tumour site or intravenously.
Mouse subcutaneous sponge angiogenesis assay
Cellspon cellulose sponges (thickness 2 mm, diameter
10 mm, Cellomeda; Turku, Finland) were implanted
under the skin of NMRI nude mice [26]. Operations were
performed under general anaesthesia induced by intra-
peritoneal injections of Domitor™ (Pfizer, Orsay, France)
and Imalgene™ (Merial, Lyon, France). The sponges
were hydrated with 50 μL of PBS or FGF-2 (200 ng/50 μL;
FGF-2: recombinant human FGF-basic, Eurobio Abcys
S.A., Les Ullis, France), or 104 hMSCs were deposited
on the sponge surface. Each group contained five mice.
For the FGF-2 group, FGF-2 (50 μL) was again injected
into the sponges through the skin on day 2 and 3. At 7
days after implantation, the mice were anesthetised, and
the sponges were rapidly excised and photographed. Each
sponge was then homogenised in 1 mL RIPA lysis buffer
with protease inhibitors, and the supernatants were
subjected to haemoglobin quantification using Drabkin’s
reagent (Sigma-Aldrich, Saint-Quentin Fallavier, France),
expressed as mg/ml.
Bioluminescence and three-dimensional fluorescence
in vivo imaging
All imaging was performed under inhalational anaesthesia
(3% isoflurane) and administered to a free breathing mouse
using a nose cone. For bioluminescence imaging, mice
received an intraperitoneal injection of D-luciferin potas-
sium salt dissolved in sterile phosphate-buffered serum
(150 mg/kg) 5 min before imaging (ORCAII-BT-512G,
Hamamatsu Photonics, Massy, France), as described
previously by Jin et al. [27,28]. Semi-quantitative data
were obtained from the bioluminescence images by
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Figure 1 Lung metastasis and subcutaneous tumour models. (A) Subcutaneous tumour model. At day 0, 106 TSA-pGL3 cells/200 μL were SC
injected (n = 15). At day 7, bioluminescence imaging was performed for the three homogeneous groups. The control group was IV injected with
200 μL of PBS, the hMSCs SC group was peritumourally injected with 5 × 105 cells/200 μL PBS and the hMSCs IV group was IV injected with
5 × 105 cells/200 μL PBS. At day 14, bioluminescence and three-dimensional fluorescence imaging were performed. The mice were euthanized,
their Hb contents were measured, and the tumours were frozen for immunohistological studies. (B) Lung metastasis model. At day 0, 105
TSA-pGL3/200 μL PBS cells were IV injected (n = 8). At day 4, 200 μL of PBS (control) or hMSCs (5 × 105 cells/200 μL PBS) were IV injected. At day
10, bioluminescence and three-dimensional fluorescence imaging were performed. The mice were euthanized, and their Hb contents were
measured. Hb, haemoglobin; hMSC, human mesenchymal stem cell; IV, intravenous; PBS, phosphate-buffered saline; SC, subcutaneous; SD,
standard deviation; TSA-pGL3, TS/A-pc mouse adenocarcinoma cell line stably transfected with the luciferase reporter gene.
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Images were acquired as 16-bit TIFF files, which can pro-
vide a dynamic of up to 65,535 grey levels. Measurement of
the bioluminescence intensities (expressed as the number
of relative light units (RLU) per pixel per second for each
region of interest (ROI)), were performed using the Wasabi
software (Hamamatsu). The colour scale values displayed
by the software are adjusted to the indicated maximum
values. For the lung metastasis model, because the signal
is too low before day 5, bioluminescence signals were
measured 10 days after tumour cell injection and quantified
at the end of the experiment to determine the effects
of hMSCs on tumour growth. For subcutaneous tumours,
bioluminescence signals were followed from day 7
(before hMSC injection) to day 14 after tumour cellimplantation, and tumour growth rate was calculated
as the ratio of bioluminescence signal between D14
and D7 (D14/D7).
For three-dimensional fluorescence imaging, 200 μl
Alexa700-RAFT-c(−RGDfK-)4 (50 μM; Angiostamp
™;
Fluoptics, Grenoble, France), which targets the integrin
αvβ3, was injected intravenously through the tail vein of
each mouse. Three-dimensional fluorescence acquisition
and quantification were performed 16 h post-injection for
the tumour models and 3 h for the sponge model with the
continuous-wave fluorescence-enhanced diffuse optical
tomography system previously described by Koenig et al.
[29,30]. fDOT consists of a 690-nm laser source, a CCD
camera and a set of filters. The light source is a 35-mW
compact laser diode (Power Technology, Little Rock,
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(685AF30OD6; Melles Griot, Albuquerque, NM, USA).
The emitted fluorescence is filtered by two 700-nm
high-pass colored glass filters (RG9 OD5; Schott, Mainz,
Germany) placed in front of a NIR sensitive CCD camera
(Hamamatsu Photonics K.K., Japan) mounted with a
f/15-mm objective (Schneider Kreutznach, Bad Kreuznach,
Germany). The excitation sources described a regular
11 × 11, 2-mm spaced grid (2 × 2 cm2 field of view) over
the region of the mouse where the tumour is implanted.
Two scans were successively performed for diffusion
and fluorescence. The exposure time was automatically
computed at each laser position to use the entire dynamic
range of the camera. The two stacks of diffusion and
fluorescence images were analysed by the reconstruction
algorithm to generate a three-dimensional image [31].
The fDOT principle lies in the ability to both reconstruct
fluorescence even in highly heterogeneous-attenuating
media and handle complex geometries. The results are
presented as a three-dimensional view of the reconstructed
area. The reconstructed area is a volume meshed with a
2-mm sample rate in the x and y directions and 1 mm in
the z direction (depth) that yields a size of approximately
8 x 10 x 15 voxels and may vary slightly depending on
animal thickness. The cross-sections are presented
from bottom to top for z = 0 (ventral side) to z = 15
(dorsal side). The superimposition of the reconstructed
volumes viewed as a smooth interpolation perspective
and positioned on top of the white-light image of the
animal allowed for the generation of the final image.
The procedure time on a 3-GHz Intel Xeon was 10 min
to reconstruct the fluorescence distribution. Each
fluorescence reconstruction is presented with the same
color scale to allow for visual comparison. The scale is
provided in arbitrary units because the tomography
produces relative values unless a standard calibration
has been performed Keramidas et al. [32].
CD31, αSMA and Ki67 immunohistochemistry
Frozen sections (8 μm) from subcutaneous tumours
were fixed in acetone for 10 min. Sections were then
washed three times for 5 min each in Tris-buffered saline
containing 0.1% Tween-20 and endogenous peroxidases
were blocked with 0.1% H2O2 in methanol for 20 min.
Sections were then sequentially incubated for 1 h with a
rat monoclonal anti-CD31 antibody (MEC13.3; 1:500; BD
Pharmingen, Pont de Claix, France), rabbit anti-Ki67
(1:100; Abcam, Paris, France) or rabbit anti-alpha smooth
actin antibody (αSMA; 1:200; Abcam, Paris, France) and for
1 h with goat anti-rat (1:500; Cell Signaling Technology,
Danvers, MA, USA) or goat anti-rabbit (1:200; Dako, San
Antonio, TX, USA) secondary antibodies, as appropriate.
Peroxidase activity was revealed using diaminobenzidine
tetrachloride as a chromogen (Dako; San Antonio, TX,USA). Sections were counterstained with haematoxylin
and mounted.
Immunohistochemical staining against the endothelial
marker CD31 was followed by observation under a low
magnification scope (100×) for five fields of view of each
tumour (five tumours by condition). Then, vessel length
and quantity were measured in each of these areas using
ImageJ software [33]. All counts were performed in a
blinded manner.
After immunohistochemical staining against Ki67 and
αSMA, slides were observed under a high magnification
microscope (200×). For Ki67, six to nine areas were
photographed for each tumour. For αSMA, two to nine
areas were photographed for each tumour. These photo-
graphs were analysed using the ImmunoRatio plug-in from
ImageJ software [33]. The Ki67 index and the percentage of
αSMA positive cells were evaluated in a blinded manner
and calculated as the number of positive cells divided by all
tumour cells in one field.
RNA isolation and RT-PCR
Total RNA was extracted from tumours and organs with
TRIzol™ (Invitrogen, Cergy Pontoise, France). The total
RNA was quantified using a Nanodrop ND-2000 instru-
ment (NanoDrop Technologies, Thermo Fisher Scientific,
Wilmington, DE) and reverse transcription was performed
on 1 μg total RNA with SuperScript III™ RNaseH reverse
transcriptase (Invitrogen, Cergy Pontoise, France) under
the conditions recommended by the manufacturers.
Before PCR, quantities of cDNA samples were adjusted
to yield equal amplifications of the mRNA encoding
the housekeeping gene GAPDH (Forward: ACTCCACTC
ACGGCAAATTC, Reverse: TCTCCATGGTGGTGAAG
ACA). PCR for GAPDH and human CD90 (Forward:
CCAACTTCACCAGCAAATACAA, Reverse: ACTGTGA
CGTTCTGGGAGGA) were performed in a final volume
of 25 μl containing 1 × PCR buffer, 2 mM MgCl2, 200 μM
dNTPs, 400 nM each primer, 0.5 U Taq polymerase
(GoTaq™ Hot Start polymerase; Promega, Charbonnières,
France). The PCR conditions were: step 1, 95°C for 30 sec,
step 2, 62°C for 30 sec, step 3, 72°C for 30 sec. To ensure
semi-quantitative results in the RT-PCR assays, the number
of PCR cycles was selected to be in the linear range of
amplification for each set of primers (n = 30 for GAPDH
and n = 35 for hCD90). PCR products were separated
and visualised after electrophoresis on 2% agarose gels
containing 1 μg/ml ethidium bromide.
Statistical analyses
Statistical analyses were performed using StatView™
(SA, Cary, NC, USA). All results are expressed as the
mean ± standard deviation. Comparisons between groups
were performed using a two-tailed Student’s t test.
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Figure 2 Effects of hMSCs on tumour growth. (A) Representative whole-body bioluminescence images of nude mice bearing SC tumours
after injection with 106 TSA-pGL3 cells before hMSC treatment (day 7) and treated with hMSCs (5 × 105 cells; SC or IV injection; day 14) or
PBS (control) (n = 4 to 5 mice/group; representative data from one of three different experiments are shown). (B) Box plots of tumour
growth in each group. Tumour growth rate was calculated as the ratio of the bioluminescence imaging values obtained at days 14 and 7
(D14/D7) after tumour cell inoculation. The results are expressed as the mean ± SD. *P <0.05. (C) The xenograft tumour volumes of the mice
were determined at the indicated time points. hMSC were injected at day 7. Data are expressed as mean ± SD. # indicates P = 0.01 by
Student's t test (control vs. hMSC SC); $ indicates P = 0.07 by Student's t test (control vs. hMSC IV). (D) Representative whole-body
bioluminescence images of nude mice bearing lung tumours after IV injection with 105 TSA-pGL3 cells and hMSC treatment (5 × 105 cells; IV
injection; hMSCs) or PBS (control) (n = 4 mice/group). (E) Box plots of bioluminescence imaging results obtained at day 10 after tumour cell
inoculation. The results are expressed as the mean ± SD. *P <0.05. (F) Photographs of representative SC tumours stained with haematoxylin
and a Ki67 antibody at day 14 and visualised at 200× magnification. (G) Box plots of Ki67+ proliferating tumour cells. The results are
expressed as the mean ± SD (n = 6 to 9 photographs/tumour; five mice/group; ***P <0.0001). hMSC, human mesenchymal stem cell; IV,
intravenous; PBS, phosphate-buffered saline; SC, subcutaneous; SD, standard deviation; TSA-pGL3, TS/A-pc mouse adenocarcinoma cell line
stably transfected with the luciferase reporter gene.




























Figure 3 Detection of hMSCs at different timepoints after IV
injection. Different tissues/organs were collected at various
timepoints (day 1 (D1) and 7 (D7); n = 3) after the infusion of
hMSCs. RNA was extracted from these tissues and analysed by
RT-PCR. Human-specific CD90 (hCD90) and GAPDH mRNA
expression were detected by electrophoresis in a 2% agarose gel
(hCD90 product size: 139 bp, GAPDH product size: 170 bp). bp, base
pair; hMSCs, human mesenchymal stem cells; IV, intravenous; RT-PCR,
reverse-transcriptase polymerase chain reaction.
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hMSCs derived from bone marrow inhibit tumour growth
in vivo
Several reports have indicated that MSCs may influence
tumour progression in different tumour types (reviewed by
Klopp et al. [34]). In the present study, we investigated the
effect of systematically or subcutaneously delivered hMSCs
on TSA-pGL3 tumours (Figures 1 and 2). First, tumour
cells were implanted SC and 7 days later, when tumours
were macroscopically detectable, hMSCs were injected IV
or SC in the periphery of the tumour (Figure 1A). In the
second model, in the lung metastatic model, tumour cells
were injected IV, followed by an IV injection of hMSCs 4
days later (Figure 1B). The injection of hMSCs alone did
not result in tumour formation (data not shown). Tumour
initiation and growth was followed and quantified by
non-invasive bioluminescence imaging and calliper when
possible (Figure 2A-E). In each tumour model, hMSC
administration decreased the tumour growth rate and led
to a delay in disease progression. Indeed, as shown in
Figure 2B at day 14, bioluminescence rate (D14/D7) within
subcutaneous tumours was lower when hMSCs were inoc-
ulated near the tumour site (control vs. hMSC SC: 2.88-
fold; P = 0.03) or by the IV route (control vs. hMSC IV:
2.73-fold; P = 0.05). This also corresponded to a slight de-
crease in tumour volumes (Figure 2C). These results were
confirmed by repeating the experiments using hMSCs
from two other donors (data not shown).
In the lung metastasis model, at day 10 after IV inocula-
tion with TSA-pGL3 cells, mice also injected with hMSCs
exhibited a 2.03-fold (P = 0.0264) smaller bioluminescence
signal than the control mice (Figure 2D-E).
At day 14, animals were euthanized and the tumours
were cryopreserved. Analyses of cell proliferation were
performed by Ki67 labelling in sections from subcuta-
neous TSA-pGL3 (control) and TSA-pGL3 + hMSCs
tumours (see Figure 2F-G). In the control tumours,
12.7 ± 7.6% of cells were Ki67 positive. The presence
of hMSCs dramatically reduced the percentages of
Ki67-positive cells, to 1.9 ± 1.9% and 1.7 ± 1.5%, when
hMSCs were injected at the tumour periphery or IV,
respectively (P <0.0001). The anti-proliferation effect
was not significantly different when the hMSCs were
injected systematically or near the tumour site, suggesting
that the inhibitory effect of hMSCs on tumour cell growth
could be indirect. Indeed, one day after hMSCs IV injec-
tion, human CD90 mRNA expression was detected by
RT-PCR in different tissues and organs, including sub-
cutaneous tumours (Figure 3), whereas the presence of the
human CD90 mRNA was no longer detectable 7 days later.
hMSCs stimulate in vivo angiogenesis
We then hypothesised that the influence of hMSCs on
tumour growth was mediated by an indirect effect ontumour microenvironment and especially on the formation
of blood vessels. We thus evaluated the capacity of hMSCs
to induce angiogenesis using a mouse subcutaneous sponge
assay [35] (Figure 4). When poorly angiogenic cellulose
sponges are engrafted under the skin, very few blood
vessels were observed seven days after their engraft-
ment (PBS condition), and thus their haemoglobin
(Hb) content after dissection was low (1.695 mg Hb/mL).
In contrast, in hMSC- or FGF-2-treated sponge implants,
a strong angiogenic response was observed, with a large
invasion of the sponge by neo-formed blood vessels
(Figure 4C).
This effect was quantified (1) by three-dimensional
Alexa700-RAFT-c(−RGDfK-)4 fluorescence imaging
(Figure 4A and 4B) and (2) by measuring the Hb content
of the sponges (Figure 4D). The RGD-mediated fluores-
cence was 1.7-fold higher in sponges containing hMSCs
compared to control sponges, suggesting an augmentation
of the number of proliferative neo-endothelia known to
overexpress the αvß3 integrin. This pro-angiogenic activity
of hMSCs was similar to that obtained after injection of
FGF-2 (Figure 4B, P >0.05). Similar results were obtained
when we quantified the Hb content in the sponges instead
of using the RGD-based assay. Again, hMSC treatment was
as pro-angiogenic as FGF-2 treatment (3.094 mg Hb/mL ±
0.816 for hMSCs and 2.939 mg Hb/mL ± 0.824 for FGF-2)
(Figure 4D). These results confirm the in vivo pro-























































Control PBS Control FGF-2 hMSC
Figure 4 hMSCs promote angiogenesis in an in vivo sponge model. NMRI nude mice bearing a subcutaneous cellulose sponge treated with
PBS (negative control) or FGF-2 (200 ng; positive control) or hMSCs (104 cells) under the dorsal skin. (A) Representative three-dimensional
fluorescence images of mice after IV injection of 50 μM Alexa700-labeled RAFT-c(−RGDfK-)4. (B) Box plot of fluorescence intensity, recorded as
photons per pixel for a specified region of interest (ROI). The data are expressed as the mean ± SD (n = 3 to 6). (C) Animals were euthanised on
day 7, and the sponges were photographed. (D) The amount of haemoglobin (Hb) was higher in the FGF-2- and hMSC-treated groups than in
the PBS-treated group. The data are expressed as the mean ± SD of two experiments (12 mice in each group; **P <0.0007). hMSC, human
mesenchymal stem cell; IV, intravenous; PBS, phosphate-buffered saline; SC, subcutaneous; SD, standard deviation.
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reorganisation
To determine whether the influence of hMSCs on tumour
growth could be related to the pro-angiogenic properties of
the cells, we evaluated the vascularisation of the tumours
after hMSC inoculation.
In vivo imaging of subcutaneous or lung tumours using
Alexa700-RAFT-c(−RGDfK-)4 was performed (Figure 5A,
B, D, E), and we also quantified the Hb content of the
tumours after euthanasia (Figure 5C and 5F). No significant
difference between mice injected with cancer cells alone
or cancer cells and hMSCs was observed in either assay.
We also found that the level of mouse CD31 mRNAexpression was not affected by the presence of hMSCs
(data not shown). We thus concluded that the treatment
of the mice with hMSCs did not modify the overall
amount of endothelial cells or the blood content of
the tumours.
We then determined whether the vessel structure
was different in the presence of hMSCs. Sections of
subcutaneous tumours were stained with an antibody
directed against CD31 to visualise the blood vessels
(Figure 6A, B and C). Blood vessel density and blood
vessel length were then quantified. The results of this
analysis revealed that vessel area decreased in mice injected

























































































































Figure 5 In vivo evaluation of tumour angiogenesis. (A and D) Representative three-dimensional fluorescence images of mice bearing SC tumours
(A) or lung tumours (D) treated or not with hMSCs, after IV injection of 50 μM Alexa700-labeled RAFT-c(−RGDfK-)4. (B and E) Box plot of fluorescence
intensity, recorded as photons per pixel for a specified region of interest (ROI). The data are expressed as the mean ± SD (n = 4 to 5). (C and F) Amount
of haemoglobin (Hb) quantified in subcutaneous (C) or lung (F) tumours. The data are expressed as the mean ± SD. hMSC, human mesenchymal stem
cell; SC, subcutaneous; SD, standard deviation.
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cells alone. We observed not only a decrease in the number
of tumour vessels but also an increase in vessel length. In-
deed, the median vessel length was 85 μm for tumour cells
alone and 323 μm (P <0.0001) and 290 μm (P = 0.0016)
when hMSCs were injected SC or IV. In addition, analyses
of vessel maturation were performed by αSMA labelling(pericyte staining) in sections from subcutaneous TSA-
pGL3 (control) and TSA-pGL3 + hMSCs tumours (see
Figure 6D). In the control tumours, 1.06 ± 0.89% of cells
were αSMA positive. The presence of hMSCs increased
the percentages of αSMA-positive cells, to 2.32 ± 0.79%
(P = 0.076) and 7.55 ± 4.51% (P <0.0001), when hMSCs



















































































Control        hMSC SC    hMSC IV 
*** 
Figure 6 hMSCs modify the SC tumour vessel structure. (A) Images of vessels in TSA-pGL3 tumours in xenograft tumour models with and
without injection (SC or IV) of hMSCs after staining with haematoxylin and a CD31 antibody (100× magnification). Scale bar = 200 μm. (B and C)
Quantitative analyses of vessel density (B) and vessel length (C) The results are expressed as the mean ± SD. (n = 5 mice; six images/mouse; *P <0.05,
**P = 0.0016, ***P <0.0001). (D) Box plots of αSMA+ cells in tumour. The results are expressed as the mean ± SD (n = 2 to 9 photographs/tumour; two
to five mice/group; ***P <0.0001). hMSC, human mesenchymal stem cell; IV, intravenous; SC, subcutaneous; SD, standard deviation.
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hMSCs does not modify the global number of CD31 and
αvß3-integrin positive tumour cells, nor does it change
the blood content of the tumours, but it does affect the
structure and shape of the blood vessels.
Discussion
Numerous studies have clearly demonstrated that hMSCs
can play an important role in cell therapy treatment
against cancer. However, the reported results are highly
controversial, and hMSC-based treatments are described
as both promoting [10,11,21,36,37] and preventing tumour
growth [8,38,39]. This dual effect can be observed in the
same B16 melanoma model [22,40] and thus does not
depend on tumour type. Some discrepancies could also
be attributable to differences in the timing of hMSC
administration (co-injection versus sequential injection), as
suggested by Klopp et al. [34]. Indeed, when we subcutane-
ously co-injected hMSCs and tumour cells, we observed an
increase of tumour growth compared to tumour cells alone
(data not shown).In this study, we demonstrated that the systemic or
peritumoural injection of hMSCs resulted in a decrease
in the pre-established tumour growth in mice using two
different tumour models (TSA-pGL3 lung tumours and
TSA-pGL3 subcutaneous tumours).
The effect of inhibition on tumour growth is clearly
correlated with a decrease in the Ki67 labelling index.
Our hypothesis is that this effect could be indirect
because we observed the same result when hMSCs are
injected by means of the IV route or directly beside the
tumour site. Moreover, these results are obtained even
when hMSCs are not or only poorly and transiently
detected at the tumour site. In our model using nude
mice, hMSCs were detected by RT-PCR one day after IV
injection in the tumour as well as in the lung, liver
and spleen, as previously described [41-44], but were
undetectable when the mice were euthanized 7 days
later. The tropism of hMSCs for tumours has been
described in the literature [45-47] but remains marginal,
with only 2% to 5% of injected cells found in the tumour
masses [48]. It has been proposed that this tumour-growth
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soluble factors [9], which could act on tumour cells or on
the tumour microenvironment. Prockop and colleagues
proposed a model of myocardial infarction in which the
action of hMSCs is indirect and related to inflammation.
Moreover, the appearance of the hMSCs in the heart was
transient and they disappeared by 48 hours [49,50].
Because different studies have demonstrated that MSCs
play a role in angiogenesis, we decided to evaluate the
influence of hMSCs on tumour angiogenesis. In a first
assay, we used an in vivo physiological model of angio-
genesis based on the introduction of a cellulose sponge
template under the skin of the mouse and demon-
strated the pro-angiogenic activities of hMSCs. Indeed,
the in vivo angiogenic effect of hMSCs is as strong as
the effect of basic FGF-2. This result was consistent
with published data from another angiogenic, but less
physiological, model of in vivo Matrigel implantation
[14-16]. However, the pro-angiogenic activity of hMSCs
was not confirmed in a pathological situation such as
that in a tumour. Interestingly, the treatment of tumours
with hMSCs was not associated with a modification of
three-dimensional RGD-based fluorescence imaging or
an increasing amount of haemoglobin. Nevertheless, we
observed an effect on the tumour vasculature, characterised
by a decrease in the number of blood vessels and an
increase in the vessel size, leading to a more structured
vascular architecture. The key role of hMSCs in regulating
vessel maturation and functionality has already been
described [51,52]. It is well known that tumours have
an abnormal vascular network characterised by dilated,
tortuous, and hyperpermeable vessels, and ultimately
poor tumour oxygenation [53]. We also observed an in-
creasing of the αSMA-positive cells in tumours after hMSC
injection. It has been shown that pericyte maturation within
tumours contributes to vascular normalisation [54]. In par-
allel, clinical evidence suggests that vascular normalisation
occurs in human patients receiving anti-angiogenic agents
[55] and that there is synergism between anti-VEGF
therapy and systemic chemotherapy [56,57]. It will be
interesting to test the injection of hMSCs associated
with a conventional chemotherapy in our model. This
approach has been evaluated by Pessina et al. [58] using
MSCs as a vehicle for paclitaxel delivery. These authors
observed an inhibition of endothelial cell proliferation
in vitro and a diminution of B16 tumour growth but did
not analyse the structure of the tumour blood vessels.
Conclusions
In this study, we demonstrated that hMSCs administration
decrease pre-established tumour growth, when hMSCs
were injected systemically or directly into contact with the
tumour. This effect is clearly correlated with an inhibition
of tumour cell proliferation. More, whereas we have shownthat the hMSCs induced angiogenesis in vivo, these
cells do not alter the overall tumour angiogenesis.
However, administration of hMSCs induces significant
remodelling in tumour vasculature.
In summary, our results confirm that MSCs could be
interesting to use for the treatment of pre-established
tumours, particularly in combination with other therapies.
However, the complex mechanisms of hMSC action remain
to be characterised further.
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